U.S. Benefits Manager Baulks After Novartis Values Gene Therapy at $4-5 Million

By REUTERS
NYT Europe
Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.
Published date: November 23, 2018 at 08:07AM
Reuters
New York Times article